Dr. Agarwal's Health Care / Q3-FY26

Read the quarter in context.

A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Positive2026-02-10Back to AGARWALEYE

Revenue

₹530 Cr

verified against source

Revenue YoY

23%

reported change

EBITDA

₹155 Cr

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
Revenue (₹ Cr)PositiveWatchNegative
2 actual records
Actual quarterly Revenue (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q1 FY26: 487.3 · Positive source sentiment · 2025-08-14Q1 FY26Q3 FY26: 530 · Positive source sentiment · 2026-02-10Q3 FY26530487.3
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Dr. Agarwal's Health Care delivered a strong Q3 FY26 with revenue from operations growing 23% YoY to ₹530 crore, driven by volume and value growth. EBITDA grew 21.3% YoY to ₹155 crore with margins stable at 28.4%, while PAT surged 55% YoY to ₹44 crore aided by lower finance costs. Surgical volumes grew 11.6% YoY, with high-end cataract procedures rising to 28% of cataract revenue and robotic cataract surgeries up 83% YoY. The company added 38 new facilities in 9M FY26 and plans 16 more in Q4, targeting 55-60 annual additions. Management reiterated confidence in meeting full-year guidance. Key risk: slower-than-expected ramp-up in newer geographies like Delhi and Ethiopia could pressure near-term margins.

Colored figures show movement against the previous available record.

Guidance to track

  • Management guided to add 55-60 new facilities every year, increasing network size by ~20% annually.
  • Plan to launch 16 new centers in Q4 FY26, including 11 surgical centers across south, west, and north regions.
  • Management committed ₹310 crore capex for FY26; ₹275 crore already spent in 9M FY26.
  • The merger process with subsidiaries is expected to be completed by Q3 or Q4 of FY27, pending regulatory approvals.

Risks flagged

  • New facilities in non-core markets like Delhi and Ethiopia may take 15-18 months to break even, potentially pressuring near-term margins.
  • Refractive surgery volumes were slower this year due to industry-wide softness, which could persist and impact growth.
  • Analyst noted a drop in revenue per facility in the east region; management attributed it to early-stage facilities, but sustained underperformance could signal competitive pressure.
  • New labor codes could increase employee costs; management assessed impact as not material currently but continues to monitor.

Key quotes

  • Despite us being able to scale up this many new centers, we've been able to maintain our margins which basically means that we are ramping up our new centers a lot faster to break even.
  • Our same store sales growth is north of about 13.5% which is again a very very healthy sign.
  • Ethiopia is one of the growing markets in entire Africa. So the potential opportunity that exists today with the lack of services with the number of people coming into Addis Ababa is lucrative according to us right now.

Research modules

Go one layer deeper.